Omeprazole was effective in the short term for uninvestigated dyspepsia
- Una CombinaciÃ³n Racional en el Tratamiento de la Dispepsia Funcional. Velázquez de Campos, Omaira; Veitía, Guillermo // Informe Medico;2014, Vol. 16 Issue 4, p142
Several pathogenic and symptomatic factors interact in functional dyspepsia. This disease may have functional and organic causes; the organic causes may be benign in its origin as peptic ulcer is; or malignant such as gastric cancer. The Rome II Committee defined functional dyspepsia as the...
- Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). Delaney, Brenden C.; Qume, Michelle; Moayyedi, Paul; Logan, Richard F.A.; Ford, Alexander C.; Elliott, Cathy; McNulty, Cliodna; Wilson, Sue; Hobbs, F.D. Richard // BMJ: British Medical Journal (International Edition);3/22/2008, Vol. 336 Issue 7645, p651
Objective To determine the cost effectiveness of Helicobacter pylori "test and treat" compared with empirical acid suppression in the initial management of patients with dyspepsia in primary care. Design Randomised controlled trial. Setting 80 general practices in the United Kingdom....
- Subacute Cutaneous Lupus Erythematosus Induced or Exacerbated by Proton Pump Inhibitors. Dam, Claus; Bygum, Anette // Acta Dermato-Venereologica;2008, Vol. 88 Issue 1, p87
A letter to the editor is presented concerning the treatment of subacute cutaneous lupus erythematosus using proton pump inhibitors.
- PPIs and clopidogrel. // Critical Care Alert;May2009 Pharmacology Watch, p2
The article focuses on the efficiency of proton pump inhibitors (PPIs) in reducing the effect of clopidogrel on platelet aggregate.
- Pantoprazole intravenous. My-Trang Le; Cano, Steven // Drug Utilization Review;Nov2001, Vol. 17 Issue 11, p1
Presents information on pantoprazole, an intravenous form of the benzimidazole proton pump inhibitor class drug. Pharmacokinetics; Pharmacodynamics; Dosage and administration.
- Biological Plausibility Between Proton Pump Inhibitory Therapy and Hip Fracture: Hypermocysteinemia Can Be the Link. Roblin, Xavier; Phelip, Jean Marc // American Journal of Gastroenterology;Apr2009, Vol. 104 Issue 4, p1052
A letter to the editor is presented in response to the article regarding the biological validity of proton pump inhibitory therapy (PPI) and hip fracture in the previous issue.
- It Is Difficult to Discontinue PPI Treatment in Patients With GERD. Bjornsson, Einar // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p367
A letter to the editor is presented in response to an article regarding the development of dyspepsia in healthy volunteers after stopping proton-pump inhibitors (PPI) therapy.
- Omeprazole. // Reactions Weekly;8/21/2010, Issue 1315, p37
The article describes the case of a 52-year-old woman who took omeprazile for acid reflux and developed burning mouth syndrome-like symptoms.
- Omeprazole/pantoprazole. // Reactions Weekly;8/21/2010, Issue 1315, p37
The article describes the case of a 60-year-old man who had neutropenia initially while taking omeprazole and later during treatment with pantoprazole.